Varicella-zoster virus viral antigens (VZV antigens)

Varicella-zoster virus (VZV) viral antigens are essential proteins encoded by the Human alphaherpesvirus 3, which is the causative agent of varicella (chickenpox) and herpes zoster (shingles). Among these, Glycoprotein E (gE) is the most abundant and immunogenic, playing a pivotal role in viral attachment, membrane fusion, and cell-to-cell spread (Source: PubMed, PMID: 11831707). These antigens serve as the primary targets for both the innate and adaptive immune systems, triggering the production of neutralizing antibodies and the activation of T-cell responses. In clinical practice, VZV antigens are the basis for highly effective vaccines; for example, the recombinant zoster vaccine (Shingrix) utilizes a purified gE antigen to elicit a robust immune response against shingles reactivation (Source: FDA, Shingrix Label). Additionally, live-attenuated vaccines like Varivax use the entire suite of viral antigens to provide immunity against primary infection. Passive immunization with Varicella-Zoster Immune Globulin (VZIG) also targets these antigens to provide immediate, temporary protection for vulnerable populations (Source: CDC, VZV Clinical Overview). Understanding the molecular structure of these antigens is critical for developing next-generation therapeutics and monitoring vaccine efficacy through antibody titers.

Other names

Human alphaherpesvirus 3 antigensVZV glycoproteinsVZV proteinsVaricella-zoster virus envelope glycoproteins

Stimulation of active humoral and cellular immunity through exposure to viral proteins (vaccines) or provision of passive immunity via exogenous antibodies (immunoglobulins) to neutralize viral particles.